0.19USD
802.00 KUSD
40.21 MUSD
3.20 M
About Interpace Biosciences, Inc.
Sector
Industry
CEO
Thomas W. Burnell
Website
Headquarters
Parsippany
Employees (FY)
108
Founded
1986
ISIN
US46062X3035
FIGI
BBG000BDV8X0
Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IDXG is 1.47 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Interpace Biosciences, Inc. stocks are traded under the ticker IDXG.
Interpace Biosciences, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
IDXG stock is 10.95% volatile and has beta coefficient of 3.27. Check out the list of the most volatile stocks — is Interpace Biosciences, Inc. there?
IDXG earnings for the last quarter are 0.09 USD whereas the estimation was −0.08 USD which accounts for 212.50% surprise. Estimated earnings for the next quarter are −0.01 USD. See more details about Interpace Biosciences, Inc. earnings.
Interpace Biosciences, Inc. revenue for the last quarter amounts to 11.03 M USD despite the estimated figure of 13.00 M USD. In the next quarter revenue is expected to reach 14.00 M USD.
Yes, you can track Interpace Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
IDXG stock has risen by 1.38% compared to the previous week, the month change is a 9.82% fall, over the last year Interpace Biosciences, Inc. has showed a 17.60% increase.
IDXG net income for the last quarter is 889.00 K USD, while the quarter before that showed −614.00 K USD of net income which accounts for 244.79% change. Track more Interpace Biosciences, Inc. financial stats to get the full picture.
Today Interpace Biosciences, Inc. has the market capitalization of 6.48 M, it has decreased by 3.33% over the last week.
No, IDXG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IDXG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Interpace Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 108.00 employees. See our rating of the largest employees — is Interpace Biosciences, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Interpace Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Interpace Biosciences, Inc. stock shows the neutral signal. See more of Interpace Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Interpace Biosciences, Inc. EBITDA is 3.81 M USD, and current EBITDA margin is 9.54%. See more stats in Interpace Biosciences, Inc. financial statements.